Tag: recombinant DNA technology industry

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Recombinant DNA Technology Market Forecast: Value Set To Climb From $998.83 Billion To $1414.92 Billion

The recombinant dna technology market size has seen robust expansion in recent years. It is anticipated to increase from $913.42 billion in 2025 to $998.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. The growth observed in the preceding period can be attributed to several factors including the expansion of molecular biology research, a rising incidence of chronic diseases, advances in biologics development, increased academic and government research funding, and the early commercialization of recombinant therapies.

The recombinant DNA technology market is projected to witness robust expansion in the coming years. Its valuation is set to climb to $1414.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This anticipated growth within the forecast period is driven by factors such as increasing investments in gene therapy development, a rising demand for personalized medicine, the broadening of CRISPR-based applications, a growing focus on sustainable bioproduction, and enhanced collaboration between academia and industry. Significant trends expected during this period include a greater adoption of gene editing platforms, an increase in the development of recombinant vaccines, the expanding utilization of advanced expression systems, an enlargement of cell and gene therapy pipelines, and a heightened emphasis on scalable biomanufacturing.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=69523130&type=smp&name=Recombinant%20DNA%20Technology%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Recombinant DNA Technology Market Growth Factors Behind Sustained Expansion

The increasing creation of genetically modified crops is projected to stimulate the expansion of the recombinant DNA technology market going forward. Genetically modified crops are defined as plants whose genetic composition has been purposefully altered using advanced biotechnological methods. Recombinant DNA (rDNA) technology finds application in genetically modified (GM) crops through a process that includes isolating genes for desired characteristics, assembling recombinant DNA, inserting it into recipient crop cells, screening for successful integration, propagating transgenic plants, assessing trait expression, conducting field experiments, securing necessary regulatory endorsements, and ultimately launching crops with improved attributes commercially. For example, in December 2023, according to the United States Department of Agriculture, a US-based government agency, Canada sowed 11.7 million hectares of genetically engineered (GE) crops, mainly consisting of canola, soybeans, and corn. This indicated a 4% rise from 2022, primarily driven by the growth in canola planting areas. Thus, the escalating development of genetically modified crops is propelling the growth of the recombinant DNA technology market.

Recombinant DNA Technology Market Segment Analysis And Revenue Potential

The recombinant dna technology market covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

Recombinant DNA Technology Market Industry Trends Fueling Future Revenue Growth

Major companies operating in the recombinant DNA technology market are increasingly focusing on incorporating advanced gene-editing techniques like clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering to improve precision, therapeutic efficacy, and targeted genome modification. CRISPR-based recombinant DNA engineering is a molecular method that utilizes a guide RNA and the Cas9 enzyme to locate and cut specific DNA sequences, facilitating targeted gene correction, controlled DNA insertion, and efficient genomic modification. For instance, in December 2023, Vertex Pharmaceuticals, a US-based biotechnology company, along with CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, obtained approval from the US Food and Drug Administration for Casgevy, a CRISPR-enabled recombinant DNA therapy developed for the treatment of sickle cell disease and transfusion-dependent beta thalassemia by editing a patient’s own stem cells to increase fetal hemoglobin production. Casgevy features precise DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy enhances treatment outcomes by enabling lasting gene correction, reducing reliance on conventional treatments, and supporting long-term clinical benefits.

Recombinant DNA Technology Market Industry Leaders And Competitive Landscape

Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc

View The Full Recombinant DNA Technology Market Report:

https://thebusinessresearchcompany.com/report/recombinant-DNA-technology-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Recombinant DNA Technology Market Regional Analysis And Top Geography

North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Recombinant DNA Technology Market Increase Between 2026 And 2030?

The market for recombinant DNA technology has shown robust growth over recent years. Forecasters predict it will expand from $913.42 billion in 2025 to reach $998.83 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. Historically, this growth can be linked to factors such as the broader scope of molecular biology research, a greater occurrence of chronic diseases, advancements in biologics development, increased financial support for research from academic institutions and governments, and the initial market introduction of recombinant therapies.

The recombinant dna technology market size is projected to experience robust expansion in the coming years, with its valuation set to reach $1414.92 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.1%. This anticipated growth during the forecast timeframe stems from several factors, such as escalating investments directed towards gene therapy development, a surging need for personalized medicine, the broadening scope of CRISPR-based applications, an intensified focus on sustainable bioproduction, and heightened cooperation between academic institutions and industrial sectors. Key developments anticipated in this period encompass the wider embrace of gene editing platforms, an increase in the creation of recombinant vaccines, a greater utilization of advanced expression systems, the enlargement of cell and gene therapy pipelines, and a stronger emphasis on scalable biomanufacturing techniques.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Drivers Are Advancing The Recombinant DNA Technology Market Growth?

The expanding creation of genetically modified crops is anticipated to boost the recombinant DNA technology market in the future. Genetically modified crops are defined as plants whose genetic material has been deliberately modified through biotechnological methods. Recombinant DNA (rDNA) technology is applied in genetically modified (GM) crops through a process that includes isolating genes for desirable traits, creating recombinant DNA, inserting it into host crop cells, screening for successful integration, growing transgenic plants, assessing trait expression, conducting field tests, securing regulatory approval, and finally commercializing crops with enhanced characteristics. As an illustration, in December 2023, data from the United States Department of Agriculture, a US-based government agency, showed that Canada cultivated 11.7 million hectares of genetically engineered (GE) crops, mainly canola, soybeans, and corn. This constituted a 4% increase from 2022, primarily due to the growth in canola cultivation areas. Consequently, the rising development of genetically modified crops is propelling the expansion of the recombinant DNA technology market.

How Is Segment Classification Applied In The Recombinant DNA Technology Market?

The recombinant dna technology market covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

What Trends Are Influencing The Recombinant DNA Technology Market Outlook?

Leading companies within the recombinant DNA technology market are increasingly focusing on integrating advanced gene-editing methods, such as clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering, to improve precision, therapeutic effectiveness, and specific genome alterations. CRISPR-based recombinant DNA engineering is a molecular technique that utilizes a guide RNA and the Cas9 enzyme to pinpoint and cut specific DNA sequences, thereby enabling capabilities like precise gene correction, controlled DNA insertion, and efficient genomic modification. For example, in December 2023, Vertex Pharmaceuticals, a US-based biotechnology company, alongside CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, received approval from the US Food and Drug Administration for Casgevy. This CRISPR-enabled recombinant DNA therapy is designed for the treatment of sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient’s own stem cells to increase fetal hemoglobin production. Casgevy offers targeted DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy improves treatment outcomes by facilitating durable gene correction, reducing reliance on conventional treatments, and supporting long-term clinical benefits.

Which Key Players Are Active In The Recombinant DNA Technology Market?

Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc

Access The Complete Recombinant DNA Technology Market Report:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Which Region Has The Strongest Presence In The Recombinant DNA Technology Market?

North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Recombinant DNA Technology Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2026, By The Business Research Company

Plasmid Dna Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasmid-dna-manufacturing-global-market-report

Gene Delivery Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report

Dna Digital Data Storage Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Recombinant DNA Technology Market Evolve From 2026 To 2030?

The recombinant dna technology market has experienced substantial growth in recent years. It is forecast to grow from $913.42 billion in 2025 to $998.83 billion in 2026, at a compound annual growth rate (CAGR) of 9.4%. Historically, this expansion can be attributed to the broadening of molecular biology research, an increasing incidence of chronic diseases, advancements in biologics development, rising academic and government research funding, and the early commercialization of recombinant therapies.

The recombinant DNA technology market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $1414.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This expected growth during the forecast period stems from factors such as increasing investments in gene therapy development, a rising demand for personalized medicine, the broader application of CRISPR-based technologies, a growing emphasis on sustainable bioproduction, and enhanced collaboration between academic and industrial sectors. Prominent trends observed within this forecast timeframe include the increasing adoption of gene editing platforms, accelerated development of recombinant vaccines, wider use of advanced expression systems, the expansion of cell and and gene therapy pipelines, and an enhanced focus on scalable biomanufacturing.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Recombinant DNA Technology Market?

The increasing development of genetically modified crops is expected to propel the growth of the recombinant DNA technology market going forward. Genetically modified crops refer to plants whose genetic makeup has been intentionally altered using biotechnological techniques. Recombinant DNA technology is employed in GM crops through a multi-step process that involves isolating genes for desired traits, constructing recombinant DNA, introducing it into host crop cells, selecting and screening for successful integration, regenerating transgenic plants, testing for trait expression, conducting field trials, obtaining regulatory approval, and ultimately commercializing crops with improved characteristics. For instance, in December 2023, the United States Department of Agriculture reported that Canada planted 11.7 million hectares of genetically engineered crops, primarily consisting of canola, soybeans, and corn. This marked a 4% increase from 2022, driven by the expansion of canola planting areas. Therefore, the increasing development of genetically modified crops is driving the growth of the recombinant DNA technology market.

Which Segment Areas Are Covered In The Recombinant DNA Technology Market Analysis?

The recombinant dna technology market covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

What Key Developments And Trends Are Impacting The Recombinant DNA Technology Market?

Leading companies operating in the recombinant DNA technology market are increasingly adopting advanced gene-editing techniques, specifically CRISPR-based recombinant DNA engineering, to boost precision, therapeutic effectiveness, and targeted genome alterations. This CRISPR-based recombinant DNA engineering constitutes a molecular method that utilizes a guide RNA and the Cas9 enzyme to identify and cleave specific DNA sequences, thereby enabling functions such as precise gene correction, controlled DNA insertion, and efficient genomic manipulation. For example, in December 2023, Vertex Pharmaceuticals, a US-based biotechnology company, alongside CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, secured approval from the US Food and Drug Administration for Casgevy. This CRISPR-enabled recombinant DNA therapy is formulated for the treatment of sickle cell disease and transfusion-dependent beta thalassemia by editing a patient’s own stem cells to elevate fetal hemoglobin production. Casgevy offers targeted DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. The therapy improves patient outcomes by facilitating durable gene correction, decreasing reliance on conventional treatments, and supporting long-term clinical advantages.

Which Global Companies Are Actively Competing In The Recombinant DNA Technology Market?

Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc

Read the full recombinant dna technology market report here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

What Are The Leading Geographic Regions In The Recombinant DNA Technology Market?

North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Recombinant DNA Technology Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2026, By The Business Research Company

Plasmid Dna Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasmid-dna-manufacturing-global-market-report

Gene Delivery Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report

Dna Digital Data Storage Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

How is the Recombinant DNA Technology Market size predicted to change over the forecast window of 2026–2035?

The recombinant dna technology market size has experienced robust growth recently. It is projected to expand from $913.42 billion in 2025 to $998.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.4%. The factors contributing to this historical growth include the expansion of molecular biology research, the increasing incidence of chronic diseases, advancements in biologics development, a rise in academic and government research funding, and the early commercialization of recombinant therapies.

The recombinant dna technology market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $1414.92 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.1%. Factors driving this growth during the forecast period include greater investments in gene therapy development, a growing need for personalized medicine, the broadening scope of CRISPR-based applications, an intensified focus on sustainable bioproduction, and heightened collaboration between academic institutions and industrial sectors. Key trends expected over the forecast horizon involve the increasing uptake of gene editing platforms, an uptick in the development of recombinant vaccines, wider application of advanced expression systems, an expanding range of cell and gene therapy pipelines, and a stronger emphasis on scalable biomanufacturing processes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Drivers Are Contributing To The Expansion Of The Recombinant DNA Technology Market?

The expanding cultivation of genetically engineered crops is anticipated to fuel the future expansion of the recombinant DNA technology market. Genetically modified crops are plants whose genetic composition has been deliberately modified through biotechnological methods. Recombinant DNA (rDNA) technology finds application in genetically modified (GM) crops through a process that involves isolating genes for desired characteristics, creating recombinant DNA, inserting it into recipient crop cells, choosing and examining for proper integration, growing transgenic plants, evaluating trait manifestation, performing field tests, securing regulatory permission, and finally launching crops with enhanced qualities. For example, data from December 2023 by the United States Department of Agriculture, a US-based government body, shows that Canada cultivated 11.7 million hectares of genetically engineered (GE) crops, predominantly canola, soybeans, and corn. This figure indicates a 4% rise compared to 2022, primarily due to the increased acreage dedicated to canola cultivation. Consequently, the growing advancement of genetically modified crops is stimulating the expansion of the recombinant DNA technology market.

What Segment Categories Are Covered In The Recombinant DNA Technology Market?

The recombinant dna technology market covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

How Are Emerging Trends Affecting The Progression Of The Recombinant DNA Technology Market?

Major companies in the recombinant DNA technology market are focusing on incorporating advanced gene-editing techniques, such as clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering, to enhance precision, therapeutic efficacy, and targeted genome modification. This CRISPR-based recombinant DNA engineering is a molecular technique that utilizes a guide RNA and the Cas9 enzyme to locate and cut specific DNA sequences, enabling capabilities like targeted gene correction, controlled DNA insertion, and efficient genomic modification. For instance, in December 2023, Vertex Pharmaceuticals, a US-based biotechnology company, along with CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, obtained approval from the US Food and Drug Administration for Casgevy. Casgevy is a CRISPR-enabled recombinant DNA therapy developed for treating sickle cell disease and transfusion-dependent beta thalassemia through editing a patient’s own stem cells to boost fetal hemoglobin production. Casgevy is characterized by targeted DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy improves treatment outcomes by enabling durable gene correction, reducing reliance on conventional treatments, and supporting long-term clinical benefits.

Which Key Market Players Are Investing In Expansion And Innovation Within The Recombinant DNA Technology Market?

Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Which Regions Are Projected To Dominate The Recombinant DNA Technology Market In The Coming Years?

North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Recombinant DNA Technology Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2026, By The Business Research Company

Plasmid Dna Manufacturing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasmid-dna-manufacturing-global-market-report

Gene Delivery Technologies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report

Dna Digital Data Storage Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Uncover key drivers, emerging technologies, and competitive movements shaping the recombinant dna technology market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Recombinant DNA Technology Industry By 2029?

The recombinant dna technology market size has seen significant expansion in recent years. It is anticipated to increase from $858.94 billion in 2024 to $913.42 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historical period stems from elements such as healthcare demands, the development of the biopharmaceutical industry, increased investments in research and development, and the rise of personalized medicine.

The recombinant dna technology market size is set for significant growth in the coming years. By 2029, it is projected to expand to $1299.96 billion, with a compound annual growth rate (CAGR) of 9.2%. This expansion during the forecast period stems from factors such as an increase in chronic illnesses, the emergence of new biotech startups, augmented funding in biotech, the globalization of biotech markets, and increased consumer acceptance and knowledge. Prominent trends for this period include scientific breakthroughs, advancements in gene editing, the development of cell and gene therapies, the evolution of RNA therapeutics, their therapeutic uses in rare diseases, and the integration of AI and data.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

What Major Drivers Are Impacting The Recombinant DNA Technology Market?

The growing prevalence of chronic diseases is projected to boost the recombinant DNA technology market’s expansion. These conditions are defined as ailments lasting a year or more, demanding continuous medical care, limiting daily activities, or both. Recombinant DNA technology has enhanced healthcare through the development of biopharmaceutical proteins for drug applications and by replacing faulty genes with healthy ones via gene therapy, aiming to cure illnesses. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that by 2050, over 35 million new cancer cases were projected, indicating a 77% increase from the estimated 20 million cases in 2022. Hence, the rise in chronic diseases is propelling the growth of the recombinant DNA technology market.

Which Segment Categories Are Driving Maximum Growth In The Recombinant DNA Technology Market?

The recombinant dna technologymarket covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

Which Long-Term Trends Will Play A Crucial Role In The Recombinant DNA Technology Market?

Technological advancement represents a principal trend in the recombinant DNA technology market. Major companies operating in the recombinant DNA technology market are prioritizing innovative technologies to sustain their market position. For instance, in August 2022, Bluebird bio, Inc., a US-based biotechnology company, launched ZYNTEGLO, which received approval from the U.S. Food and Drug Administration (FDA). This is a one-time gene therapy that addresses beta-thalassemia by targeting its genetic cause, providing patients with the opportunity to become independent of regular red blood cell transfusions. It employs an ex-vivo lentiviral vector to modify patient cells and is the first FDA-approved gene therapy for this condition in the U.S. This breakthrough mitigates the lifelong burden of managing beta-thalassemia.

Who Are The Dominant Players In The Recombinant DNA Technology Market Today?

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Which Region Is At The Forefront Of Innovation In The Recombinant DNA Technology Market?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Cell Based Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Recombinant DNA Technology Market Size During 2025–2029?

The market encompassing recombinant DNA technology has exhibited robust expansion across recent years, with projections indicating a climb from a valuation of $858.94 billion in 2024 to $913.42 billion by 2025, reflecting a compound annual growth rate of 6.3%. This upward trajectory observed throughout the historical period primarily stems from escalating healthcare requirements, the expansion within the biopharmaceutical sector, augmented funding directed towards research and development activities, and the nascent development of individualized medical treatments.

Driven by several key factors, the recombinant DNA technology market anticipates robust expansion moving forward, projecting a valuation of $1299.96 billion by the year 2029, achieving a compound annual growth rate (CAGR) of 9.2% throughout the projection timeframe; this upward trajectory is fueled by the increasing prevalence of long-term illnesses, the emergence of new biotechnology ventures, heightened investment flowing into the biotech sector, the worldwide expansion of these markets, alongside greater public understanding and acceptance.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

What Are The Drivers Pushing New Developments In The Recombinant DNA Technology Market?

The escalating incidence of long-lasting health conditions is anticipated to fuel the expansion of the recombinant DNA technology sector. These long-term ailments, characterized by their duration of at least twelve months, demand ongoing medical attention, impose limitations on routine daily functions, or involve both circumstances. Recombinant DNA techniques have markedly advanced medical treatment by enabling the production of biopharmaceutical proteins utilized in medications and by employing gene therapy to rectify diseased states via the substitution of faulty genetic material with functional segments. Demonstrating this trend, projections from the World Health Organization, a global intergovernmental body situated in Switzerland, indicated in February 2024 that the number of new cancer diagnoses globally is expected to surpass 35 million by 2050, signifying a substantial 77 percent surge from the approximately 20 million cases estimated for 2022; consequently, this rise in chronic illnesses serves as a major catalyst for the growth trajectory of the recombinant DNA technology market.

Which Key Segments Fueling The Recombinant DNA Technology Market?

The recombinant dna technologymarket covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

What Key Innovation Trends Are Fueling Advancements In The Recombinant DNA Technology Market?

Driving forces within the recombinant DNA technology sector are heavily influenced by ongoing technological progress, compelling key market participants to concentrate on developing novel solutions to maintain their competitive standing. A prime illustration of this innovative drive is the August 2022 introduction of ZYNTEGLO by Bluebird bio, a biotechnology entity situated in the United States; this treatment, which the U.S. Food and Drug Administration (FDA) has officially sanctioned, represents a singular gene therapy intervention designed to address the root genetic mechanism of beta-thalassemia, thereby liberating affected individuals from the necessity of perpetual red blood cell transfusions. Utilizing an ex-vivo lentiviral vector to alter the patient’s own cells, this therapy achieved the distinction of being the initial FDA-approved gene therapy for this ailment within the U.S., significantly alleviating the substantial, life-long challenges associated with beta-thalassemia management.

Which Major Industry Participants Are Leading The Recombinant DNA Technology Market Growth?

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

What Are The Key Regional Factors Influencing The Recombinant DNA Technology Market Growth?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Recombinant DNA Technology Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Cell Based Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Recombinant DNA Technology Market In The Coming Years?

In recent times, the recombinant DNA technology market has experienced significant growth. Projected to increase from $858.94 billion in 2024 to $913.42 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%, this market’s upward trend is mainly due to factors like healthcare needs, expansion of the biopharmaceutical industry, increased R&D investments, and the introduction of personalized medicine.

In the coming years, the recombinant DNA technology market is projected to experience significant expansion. The market is set to increase to $1299.96 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. The predicted growth during this period can be credited to the surge in chronic illnesses, and the emergence of biotech startups, increased biotech funding, global expansion of biotech markets, consumer endorsement and learning. Notable trends for the forecast period include improvements in scientific and gene editing technologies, progress in cell and gene treatments, advancement of RNA therapeutic practices, their therapeutic uses in uncommon diseases, and the integration of Artificial Intelligence and data.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Recombinant DNA Technology Market?

The surge in chronic illnesses is projected to fuel the expansion of the recombinant DNA technology market. Chronic conditions, referred to as diseases that persist for a year or more and require constant medical attention, limit daily activities, or both. Recombinant DNA technology has revolutionized healthcare by generating biopharmaceutical proteins utilized in pharmaceuticals, and through gene therapy, which replaces faulty genes with healthy ones, aiming to cure diseases. For example, the World Health Organization, a Switzerland-based intergovernmental entity, predicted in February 2024 that over 35 million new cancer cases are anticipated by 2050, marking a 77% growth in comparison to the projected 20 million instances in 2022. Thus, the rise in chronic ailments is fueling the expansion of the recombinant DNA technology market.

Which Sub-Segments Are Driving Growth Within The Recombinant DNA Technology Market?

The recombinant dna technologymarket covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

What Future-Focused Trends Are Anticipated In The Recombinant DNA Technology Market?

The progression of technology is a significant trend in the recombinant DNA technology market. Key companies in the space are focusing on advancing technology in an effort to maintain their market position. For example, in August 2022, the US-based biotech company Bluebird bio, Inc. launched the FDA-approved ZYNTEGLO, a one-of-a-kind gene therapy which treats beta-thalassemia by targeting its genetic root, thus potentially freeing sufferers from regular red blood cell transfusions. Using an ex-vivo lentiviral vector to alter patient cells, it is the first gene therapy for this condition to receive FDA approval in the U.S. This development paves the way to lessen the ongoing management of beta-thalassemia.

Which Players Are Shaping The Competitive Landscape Of The Recombinant DNA Technology Market?

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

How Do Regional Dynamics Influence The Recombinant DNA Technology Market Performance?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Cell Based Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Recombinant DNA Technology Market Size From 2025 to 2034?

In recent years, the recombinant DNA technology market has experienced substantial growth. Its size is predicted to increase from $858.94 billion in 2024 to $913.42 billion in 2025, an annual compound growth rate (CAGR) of 6.3%. The growth in the previous period is linked to healthcare needs, expansion in the biopharmaceutical industry, increased R&D investment, and the emergence of personalized medicine.

Projected robust expansion is to be observed in the recombinant DNA technology market over the upcoming years. The market is set to reach $1299.96 billion by 2029, scaled by a Compound Annual Growth Rate (CAGR) of 9.2%. Growth during this period can be chiefly traced back to the prevalence of chronic diseases, the surface of new biotech firms, an uptick in funding for biotech, the globalisation of biotech markets along with consumer approval and wide-scale awareness. Greater scientific progress, advancements in gene editing, cell and gene therapies, the forthcoming of RNA therapeutics and potential applications in rare disease treatment, in combination with the incorporation of AI and data, are key trends expected within the forecast period.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

What Are the Core Market Drivers Propelling Growth in the Recombinant DNA Technology Industry?

The escalation in chronic illnesses is projected to spur the expansion of the recombinant DNA technology market. These chronic diseases, characterized as afflictions persisting for over a year, require ongoing medical attention, limit daily routines, or both. The advancement of healthcare through recombinant DNA technology involves the production of bio-pharmaceutical proteins utilized in medications and the substitution of unhealthy genes with healthy ones via gene therapy, aiming for disease eradication. For example, as per the World Health Organization, an intergovernmental organization based in Switzerland, by 2050, there would be an estimated 35 million new cancer cases, a 77% rise from the projected 20 million cases in 2022. Hence, the surge in chronic diseases is contributing to the growth of the recombinant DNA technology market.

How Is the Recombinant DNA Technology Market Segmented?

The recombinant dna technologymarket covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Which Regions Are Driving the Next Phase of the Recombinant DNA Technology Market Growth?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Recombinant DNA Technology Industry?

Technological progression plays a significant role in the recombinant DNA technology market trend. The leading firms in this market are concentrating on state-of-the-art technologies to maintain their market status. For example, in August 2022, Bluebird bio, Inc., a biotechnological firm based in the U.S., introduced the ZYNTEGLO, a gene treatment approved by the U.S. Food and Drug Administration (FDA). This one-time therapy targets the genetic cause of beta-thalassemia, giving patients the opportunity to liberate themselves from consistent red blood cell transfusions. Using an ex-vivo lentiviral vector, it alters patient cells and is the first gene therapy for this condition to receive FDA approval in the U.S. This significant development has reduced the ongoing task of managing beta-thalassemia.

View the full report here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

How Is the Recombinant DNA Technology Market Defined and What Are Its Core Parameters?

Recombinant DNA technology refers to fusing DNA molecules from other organisms and inserting those DNA molecules into a host organism to build a new genetic combinations useful for science, medicine, agriculture, and industry. The recombinant DNA technology is used to address health issues by creating new medications and vaccines.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8233

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Recombinant DNA Technology Market?

In recent times, the market size of recombinant DNA technology has experienced robust growth. The market is projected to expand from $858.94 billion in 2024 to $920.82 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.2%. This growth during the historical period can be credited to the increasing demands in healthcare, expansion of the biopharmaceutical industry, higher investments in research and development, and the advent of personalized medicine.

What Growth Rate Is Forecasted for the Recombinant DNA Technology Market by 2029?

In the coming years, the size of the recombinant DNA technology market is anticipated to experience significant growth, projecting to expand to a worth of $1318.72 billion by 2029 with a 9.4% compound annual growth rate (CAGR). This expected growth during the forecast period is linked to factors such as the rise in chronic diseases, the emergence of new biotech companies, heightened investment in biotech, broadening global biotech markets, as well as user acceptance and education. The forecast period is also expected to witness key trends such as scientific progress, developments in gene editing, cell and gene therapy, RNA therapeutics, rare disease therapeutic applications, and the integration of artificial intelligence and data.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Key Companies Are Shaping the Future of the Recombinant DNA Technology Market?

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

Which Factors Are Driving Demand in the Recombinant DNA Technology Industry?

The recombinant DNA technology market is predicted to expand due to a rise in chronic diseases. These diseases persist for a year or more, requiring ongoing medical care and often impacting daily activities. The development of recombinant DNA technology has revolutionized healthcare by producing biopharmaceutical proteins used in medicine and by introducing healthy genes in place of defective ones through gene therapy, aiming for a complete cure. For example, the World Health Organization, a Switzerland-based intergovernmental organization, forecasted in February 2024 that over 35 million new cancer cases would emerge by 2050, marking a 77% surge compared to the projected 20 million cases in 2022. As a result, the growing prevalence of chronic diseases is propelling the growth of the recombinant DNA technology market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

How Is the Recombinant DNA Technology Market Segmented by Several Divisions?

The recombinant DNA technology market covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

What are the Emerging Market Trends Driving the Growth of the Recombinant DNA Technology Industry?

The recombinant DNA technology market is characterized by substantial technological advancements. Many leading businesses in this market are investing in ground-breaking technologies to maintain their competitive edge. For instance, Bluebird bio, Inc., a biotechnology firm in the United States, launched the first FDA-approved gene therapy for beta-thalassemia, ZYNTEGLO, in August 2022. This one-time gene therapy targets the genetic cause of beta-thalassemia, possibly freeing patients from the need for ongoing red blood cell transfusions. By using an ex-vivo lentiviral vector to change patient cells, it represents a significant step forward in reducing the continuous management of beta-thalassemia.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Which Regions Are Driving Growth in the Recombinant DNA Technology Market?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8233

This Report Delivers Insight On:

1. How big is the recombinant dna technology market, and how is it changing globally?

2. Who are the major companies in the recombinant dna technology market, and how are they performing?

3. What are the key opportunities and risks in the recombinant dna technology market right now?

4. Which products or customer segments are growing the most in the recombinant dna technology market?

5. What factors are helping or slowing down the growth of the recombinant dna technology market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model